<DOC>
	<DOCNO>NCT00607542</DOCNO>
	<brief_summary>Oral baclofen use commonly treat spasticity child cerebral palsy . Although adult dose , safety efficacy information package insert , case child . The purpose study determine fast drug clear body , correct dose , long-term safety efficacy child spasticity .</brief_summary>
	<brief_title>Oral Baclofen Pharmacokinetics Pharmacodynamics Children With Spasticity</brief_title>
	<detailed_description>Although oral baclofen use several decade treatment spasticity adult child , little data regard pharmacokinetic ( PK ) pharmacodynamic ( PD ) property baclofen child . Therefore , pediatric guideline , include dose range , dose schedule , dose escalation strategy anticipate side effect extrapolate adult data require assumption safety efficacy child comparable adult . Furthermore , wide variability dose strategy among practitioner treat child cerebral palsy ( CP ) respect start dos , maximum dos rate dose escalation.Establishment safe effective dosing strategy child CP require understanding PK PD property baclofen child recognition individual difference may contribute divergent clinical response baclofen among child CP .</detailed_description>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>1 . Males female age 216 year , inclusive . 2 . Triceps skinfold thickness 5th 95th percentile age ( Refer Appendix 3 ) . 3 . Gross Motor Function Classification Scale ( GMFCS ) Level II V ( GMFCS classify child functional mobility Level I indicate minimal motor disability V indicate total body involvement dependence others mobility ( Palisano et al , 1997 ) . 4 . Ashworth score 2 high least one arm one leg ( knee + elbow flexor and/or extensor ) . 5 . Cerebral Palsy : Motor disability due static , nonprogressive brain injury/ malformation occur prenatally time prior age 2 year . 6 . No history baclofen use within past 4 month . 7 . Female subject , premenarchal , incapable pregnancy hysterectomy tubal ligation ; female subject sexually active capable pregnancy , use acceptable method contraception ( hormonal contraceptive , intrauterine device , spermicide barrier ) least one month prior study entry agrees continue use one duration study ; female subject sexually abstinent capable pregnancy , agree continued abstinence use acceptable method birth control ( either intrauterine device spermicide barrier ) sexual activity commence . 8 . Subject â‰¥10 year age negative urine test screen baseline alcohol , nonmedically prescribe drug abuse , history tobacco use . 1 . Hypersensitivity baclofen . 2 . Selective dorsal rhizotomy . 3 . Active intrathecal baclofen pump within past 6 month . 4 . Use botulinum toxin past 4 month use time study . 5 . Use tone alter medication ( e.g . baclofen , benzodiazepine , levodopa , trihexyphenidyl ) &gt; 3 consecutive day duration within past 4 month . 6 . Start drug product know significant cytochrome P450 enzyme inducer inhibitor within past 30 day . 7 . Orthopaedic surgery within past year time study . 8 . Abdominal surgery within past six month time study . 9 . Uncontrolled seizure ( baseline seizure frequency &gt; 1 per month history 2 prolonged seizure last longer 5 minute duration within past year . 10 . Severe behavior difficulty psychiatric disturbance 11 . Proven gastric dysmotility : know history abnormal gastric empty study and/or history vomit 3 time per week . 12 . Severe Gastroesophageal Reflux Disease : know history esophagitis ( document abnormal endoscopy biopsy ) . 13 . Malnutrition : defined triceps skin fold thickness le 5th great 95th percentile age . 14 . Renal Liver disease : Elevated bilirubin , LFTs great twice upper limit normal , reduce BUN/Cr ratio ( &lt; 5 ) , abnormal creatinine clearance clinically significant determine investigator . 15 . Abnormal CBC : Anemia , polycythemia , neutropenia , leukocytosis , thrombocytopenia , thrombocytosis clinically significant determine investigator . 16 . Pregnancy lactation . 17 . Severe respiratory cardiac disease : Requirement prolong supplemental oxygen ( &gt; 7 day ) , history clinically significant congenital heart disease , congestive heart failure cardiomegaly , and/or hospital admission within past 6 month cardiac symptom respiratory distress . 18 . Previous baclofen failure : Lack response baclofen presence unacceptable side effect . If previous baclofen therapy try &gt; 4 month prior study discontinue , decision enroll subject discretion site investigator reason discontinuation oral baclofen record . 19 . Use medication interfere measurement serum creatinine level within past 14 day ( e.g. , trimethoprimsulfa , fibric acid derivative gemfibrizol , keto acid , salicylate , cephalosporin , cimetidine , phenacemide ) . 20 . Subject test positive screen hepatitis B surface antigen hepatitis C antibody , history positive result one test . 21 . Subject know tested seropositive human immunodeficiency virus ( HIV ) subject concomitantly receive antiretroviral therapy . 22 . Any serious , unstable medical illness clinically significant abnormal laboratory assessment would adversely impact scientific interpretability unduly increase risk protocol . 23 . Subject disorder history condition , relate CP could interfere drug absorption , distribution , metabolism , excretion . 24 . Any condition would make patient</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>spasticity</keyword>
	<keyword>cerebral palsy</keyword>
	<keyword>baclofen</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>dose</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>